GOLD MOUNTAIN RESEARCH
Building innovative scientific solutions for major planetary challenges of our time
/ Our story
innovations - pragmatic, focused, and powered by deep science - are at the heart of gold mountain research
Welcome to Gold Mountain Research (GMR) of Pittsburgh, PA, whose roots go back to Stanford University.
GMR is a privately operated research center leveraging strengths in biophysics, computation, molecular design, off-the-beaten-path drug discovery, genomics, and microbiology.
Focused Innovations - the leaders “have been around the block, not the first rodeo!”
After 4 decades of service in academia, in platform biotechs (with successful exits by acquisition), in government labs (NCI in Frederick), and leadership as the Chief Executive of a non-profit research lab, we have seen many innovations launch.
As a result, GMR takes great effort applying a highly selective approach to the selection of appropriate technologies and programs within each strategic goal area.
/ Our STRATEGY
GMR pursues global-scale challenges of:
* GLOBAL HEALTH
* PULMONARY INFECTIONS and ANTI-MICROBIAL RESISTANCE (AMR)
* PREPARING IN ADVANCE for THE NEXT VIRAL PANDEMIC by VALIDATING NEW TECHNOLOGY
* FIGHTING CLIMATE CHANGE
* PREPARING IN ADVANCE for THE NEXT VIRAL PANDEMIC by VALIDATING NEW TECHNOLOGY
* FIGHTING CLIMATE CHANGE
our portfolio includes high value target spaces
- : designer enzymes : green fuels :
phased with timing matched to collaborations
: pandemic preparedness (viruses) : platform for pan-viral diagnostics from breath/saliva :
gmr programs may be computation-intensive
: chemical evolution for drug design and lead optimization : enablement of large-scale 3D description of small molecule drugs for AI :
/ Current programs
Funding and collaborations are at various stages. Key collaborations include those with affiliated non-profit platform biotechs.
TB: Tuberculosis, which kills 1.4 million annually; AMR: AntiMicrobial Resistance, the growing 21st century problem for the treatment of many bacterial infections, including TB. Infection by antibiotic-resistant bacteria threatens to throw the patient back in time to the pre-modern era, with far higher morbidity and mortality.
/ about us
strengths by 4 decades of innovation
Contact:
info@goldmountainresearch.com
The founder, Dr. Atsuo Kuki, earned his PhD in 1985 from Stanford University, and has spent 14 years in La Jolla, CA in a private computational and parallel synthesis platform biotech, acquired by a public structure-based drug R&D biotech, acquired by Parke-Davis, acquired by Pfizer… then served as an executive and technology leader within Pfizer La Jolla R&D
Academic training was in protein biophysics & spectroscopy, picosecond lasers, theoretical quantum biophysics (early days of Cray Supercomputers), Feynman path integrals, path integral Monte Carlo (quantum stat mech; electron transfer theory)
Relevant drug discovery technologies: parallel synthesis, library design, cycles of retrosynthesis and forward synthesis during lead optimization, target protein expression and crystallization, SBDD, biophysical MassSpec, chemical datasystems, JAVA (Pfizer Global Virtual Library tools)
Leader of team leaders, integration of diverse biotech and pharma R&D cultures, global Pfizer R&D technology ambassador and diplomat
Front-line experience with goverment contracting, operating as a leader in the FFRDC (Leidos) for the National Cancer Institute in Frederick, MD
President of Trudeau Institute, Saranac Lake NY. Infectious diseases research laboratory with an honored and eminent place in the history of TB (Edward Livingston Trudeau, 1984)